<DOC>
	<DOCNO>NCT02115568</DOCNO>
	<brief_summary>This exploratory registry include subject randomize receive JVS-100 treatment ( one multiple dos ) placebo one number delivery system ( e.g . endomyocardial injection , retrograde infusion ) previous Juventas clinical trial .</brief_summary>
	<brief_title>Registry Assess Safety Subjects That Have Completed Juventas Sponsored HF Protocol Under IND # 14203</brief_title>
	<detailed_description>This Registry ass ongoing safety subject include morbidity/mortality parameter relate heart failure track newly diagnose malignancy . The logistics study follow : eligible , subject must actively participate Juventas sponsor trial IND 14203 . After consent , subject follow three year post receipt investigational product time receive phone call ( every 3 month ) study site ask health . Questions aim cardiovascular related event include : - Hospitalizations - ER Visits - Unscheduled visit Cardiologist - Newly diagnose malignancy Serious Adverse Events ( SAEs ) report study ; however , data pertain event capture ( i.e . date admission diagnosis. ) . Data capture paper CRFs , collect Juventas ( designee ) enter clinical database analysis .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Participated complete Juventas sponsor heart failure study IND 14203 Unwillingness sign inform consent form Unwillingness inability receive phone call require follow assessment Subjects actively participate another regenerative medicine trial discuss sponsor prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>